Navigation Links
Misonix Expands Sales Organization for Direct Sales of the SonicOne(TM) Wound Management System and the SonaStar(R) Ultrasonic Surgical Aspirator in the United States
Date:9/1/2009

FARMINGDALE, N.Y., Sept. 1 /PRNewswire-FirstCall/ -- Misonix, Inc., (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, today announced the second expansion of its direct sales channel for the United States, which was first disclosed in June 2008. In addition to its already established, commission based, contract sales organization, the Company has added 5 experienced, highly trained Region Managers. The Region Managers will support the efforts of the contract sales representatives and will sell Misonix labeled product directly to hospitals and clinics in key markets; including, California, Texas, New York, Florida, and Illinois. In addition to the SonicOne(TM) Wound Management System, which the domestic sales team began to sell in the latter part of calendar 2008, direct to hospital sales of the SonaStar(R) Ultrasonic Surgical Aspirator have now begun. Aesculap, Inc., a division of B. Braun, the German conglomerate, who has sold SonaStar exclusively in the United States in the past, continues to market SonaStar on a non-exclusive basis.

The SonaStar is used by Neuro and General Surgeons for quick and efficient removal of both hard and soft tumors while sparing most vessels. In addition, OsteoSculpt(TM) bone sculpting technology can be employed with the SonaStar to safely remove osseous structures, thus providing access to the surgical site.

The SonicOne is an innovative, ultrasonic wound care system that offers tissue specific debridement and cleansing for effective removal of devitalized tissue and fibrin deposits while sparing viable cellular structures. The SonicOne establishes a new standard in advanced wound care and ensures progress towards patient healing.

"We are confident that by expanding our domestic sales organization we can grow our revenue in the United States," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "This sales group is designed to increase market penetration and increase revenue for these important products while building customer awareness and brand equity for Misonix. Additionally, we believe this sales team, which is very experienced in the sale of medical equipment and disposables, will provide us with the capability to effectively sell other Misonix labeled products to US clinical customers in the years to come."

About Misonix:

Misonix, Inc. (Nasdaq: MSON) designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

    Investor Relations Contact:
    Kevin McGrath
    Cameron Associates
    212-245-4577
    Kevin@cameronassoc.com


'/>"/>
SOURCE Misonix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Misonix Announces the Sale of Its Labcaire Business for up to $5.6 Million
2. Misonix Receives First Award for Forensic Equipment in China
3. Misonix Announces Participation in 2nd International Workshop on Focal Therapy
4. Misonix Subsidiary, Sonora Medical Systems, Achieves ISO 17025 Accreditation
5. Misonix Announces the Purchase of Patents From ProRhythm, Inc.
6. Misonix Announces Attendance at 22nd Annual Symposium on Advanced Wound Care
7. Misonix Announces Participation in Annual Diabetic Foot Global Conference
8. Misonix Reports Earnings for the Three and Nine Months Ended March 31, 2009
9. Misonix Announces New HIFU Distribution Agreement For Portugal
10. Misonix Announces New HIFU Distribution Agreement for Romania and Bulgaria
11. Misonix Announces New Distribution Agreement for Portugal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... (PRWEB) , ... May 24, 2017 , ... Medic ... Kids: The Surprising Truth about Pediatric Septic Shock” hosted by the Journal of Emergency ... at 2 p.m. Eastern time, will be presented by Captain Rommie Duckworth, LP, a ...
(Date:5/24/2017)... ... ... thinking of a visit to San Francisco , fall is a great time to ... , Business Architecture Associates is pleased to offer 5 days of training courses, available to ... for individuals, and as 4-½ day corporate package for up to 3 employees with the ...
(Date:5/24/2017)... ... ... Lowe is a sought after actor, and also serves as the host of the ... all aspects of life, and a new segment is being developed on podiatry, which ... is essential to people’s overall well-being, and if viewers have feet problems, they may ...
(Date:5/24/2017)... Wisconsin (PRWEB) , ... May 24, 2017 , ... ... in clean label food ingredient solutions for the food and beverage industry offers ... in food ingredient statements during the purchasing decision process. As a result, labels ...
(Date:5/24/2017)... ... 2017 , ... Dymedix® Diagnostics, Inc., the leading ... had completed the first phase of building a global distribution network. To date, ... (ROW) authorized dealers specializing in polysomnography accessories. The company plans to expand ...
Breaking Medicine News(10 mins):
(Date:5/4/2017)... Tenn. , May 4, 2017  A ... Infection Control, Ultraviolet-C light as a ... Tru-D SmartUVC,s ability to reduce bioburden on anesthesia ... bioburden reduction on high-touch, complex medical equipment surfaces ... surgical infections. "This study further validates ...
(Date:5/4/2017)... , May 4, 2017  A new ... thermoplastics and other highly-engineered materials, is being launched ... tubing has been developed in recent years to ... therapies and surgical applications. More expensive materials such ... produce microextrusion tubing due to their ability to ...
(Date:5/3/2017)... WAYNE, N.J. , May 3, 2017 /PRNewswire/ ... systems that contribute to quality enhancement and cost ... results from a study of contemporary practice demonstrating ... a first-line therapy for critically ill patients. The ... the Company,s newer large volume MEGA ® ...
Breaking Medicine Technology: